← Leaderboards
Allan Balmain
University Of California San Francisco
$39,243,725
Attributed
$43,303,821
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,586,787 · 12
By mechanism
U01$21,559,259 · 3
R35$7,176,155 · 1
OT2$6,721,823 · 1
R01$5,986,272 · 4
P30$1,389,964 · 1
P01$1,282,966 · 1
Top collaborators
- Matthew F Krummel5 shared
- William A Weiss5 shared
- Rosemary J Akhurst2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Richard J Reimer$2,497,765
- Rosemary J Akhurst$18,718,924
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMouse ModelGeneticTumorMutationGene ExpressionGenesPathway InteractionsTissuesBaseResponsePredispositionPathway AnalysisCellsSkin NeoplasmsGenotypeGenomicsLungSignal TransductionAnimalsLeadNormal Tissue MorphologyCarcinogenesisSignal Pathway
Grant awards (61)
PROMINENT - UCSF$2,615,667
OT2 · FY2025 · CA · contact PI
Systems genetics analysis of tumor evolution in the mouse$816,707
R35 · FY2025 · CA · contact PI
A network approach to interrogate cellular plasticity and drug resistance in cancer$679,232
R01 · FY2025 · CA
PROMINENT - UCSF$1,633,912
OT2 · FY2024 · CA · contact PI
A network approach to interrogate cellular plasticity and drug resistance in cancer$671,594
R01 · FY2024 · CA
PROMINENT - UCSF$1,207,862
OT2 · FY2023 · CA · contact PI
Systems genetics analysis of tumor evolution in the mouse$931,980
R35 · FY2023 · CA · contact PI
PROMINENT - UCSF$1,264,382
OT2 · FY2022 · CA · contact PI
Systems genetics analysis of tumor evolution in the mouse$931,980
R35 · FY2022 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2021 · CA
Systems genetics analysis of tumor evolution in the mouse$951,000
R35 · FY2021 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2020 · CA
Systems genetics analysis of tumor evolution in the mouse$951,000
R35 · FY2020 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$980,118
U01 · FY2019 · CA
Systems genetics analysis of tumor evolution in the mouse$922,470
R35 · FY2019 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2018 · CA
Systems genetics analysis of tumor evolution in the mouse$951,000
R35 · FY2018 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,065,613
U01 · FY2017 · CA
Systems genetics analysis of tumor evolution in the mouse$720,018
R35 · FY2017 · CA · contact PI
Genetic analysis of ras mutation specificity in skin and lung cancer$362,569
R01 · FY2017 · CA · contact PI
The Oncogenic and Tumor Suppressor Functions of the Kras isoform 4A in vivo$470,631
R01 · FY2016 · CA · contact PI
Genetic analysis of ras mutation specificity in skin and lung cancer$362,569
R01 · FY2016 · CA · contact PI
The role of the Kras4A isoform in epithelial carcinogenesis$256,027
R01 · FY2016 · CA · contact PI
The Oncogenic and Tumor Suppressor Functions of the Kras isoform 4A in vivo$458,550
R01 · FY2015 · CA · contact PI
Genetic analysis of ras mutation specificity in skin and lung cancer$361,997
R01 · FY2015 · CA · contact PI
The role of the Kras4A isoform in epithelial carcinogenesis$256,027
R01 · FY2015 · CA · contact PI
The role of the Kras4A isoform in epithelial carcinogenesis$247,562
R01 · FY2014 · CA · contact PI
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response$699,208
U01 · FY2013 · CA · contact PI
Science Leadership and Integration$608,247
U01 · FY2013 · CA · contact PI
The role of the Kras4A isoform in epithelial carcinogenesis$254,359
R01 · FY2013 · CA · contact PI
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response$759,738
U01 · FY2012 · CA · contact PI
Science Leadership and Integration$674,328
U01 · FY2012 · CA · contact PI
The role of the Kras4A isoform in epithelial carcinogenesis$269,732
R01 · FY2012 · CA · contact PI
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response$827,538
U01 · FY2011 · CA · contact PI
Science Leadership and Integration$693,027
U01 · FY2011 · CA · contact PI
GENOME ANALYSIS$289,094
P30 · FY2011 · CA · contact PI
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response$826,688
U01 · FY2010 · CA · contact PI
Science Leadership and Integration$736,629
U01 · FY2010 · CA · contact PI
GENOME ANALYSIS$285,699
P30 · FY2010 · CA · contact PI
The role of Kras2 in lung tumor susceptibility$266,285
R01 · FY2010 · CA · contact PI
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response$843,185
U01 · FY2009 · CA · contact PI
Science Leadership and Integration$499,183
U01 · FY2009 · CA · contact PI
GENOME ANALYSIS$283,525
P30 · FY2009 · CA · contact PI
The role of Kras2 in lung tumor susceptibility$266,285
R01 · FY2009 · CA · contact PI
Identification of epithelial tumor susceptibility genes$1,013,657
U01 · FY2008 · CA · contact PI
GENOME ANALYSIS$287,050
P30 · FY2008 · CA · contact PI
The role of Kras2 in lung tumor susceptibility$266,070
R01 · FY2008 · CA · contact PI
Program Project Grant$1,282,966
P01 · FY2007 · AR · contact PI
Identification of epithelial tumor susceptibility genes$1,008,772
U01 · FY2007 · CA · contact PI
Sequenom MassArray System$470,348
S10 · FY2007 · RR · contact PI
The role of Kras2 in lung tumor susceptibility$265,208
R01 · FY2007 · CA · contact PI
GENOME ANALYSIS$244,596
P30 · FY2007 · CA · contact PI
Identification of epithelial tumor susceptiility genes$1,343,723
U01 · FY2006 · CA · contact PI
The role of Kras2 in lung tumor susceptibility$271,575
R01 · FY2006 · CA · contact PI
Identification of epithelial tumor susceptiility genes$1,342,977
U01 · FY2005 · CA
Identification of epithelial tumor susceptibility genes$1,035,036
U01 · FY2004 · CA
APPROACHES TO THE ISOLATION OF SKIN TUMOR MODIFIER GENES$971,899
U01 · FY2003 · CA
APPROACHES TO THE ISOLATION OF SKIN TUMOR MODIFIER GENES$943,593
U01 · FY2002 · CA
APPROACHES TO THE ISOLATION OF SKIN TUMOR MODIFIER GENES$760,862
U01 · FY2001 · CA
APPROACHES TO THE ISOLATION OF SKIN TUMOR MODIFIER GENES$155,244
U01 · FY2001 · CA
APPROACHES TO THE ISOLATION OF SKIN TUMOR MODIFIER GENES$738,701
U01 · FY2000 · CA